Evidence map›Paper›PMID 31118701›Full record

ArticleInfection and drug resistance2019

Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype.

Georg von Massow, Damir Garcia-Cehic, Josep Gregori, Francisco Rodriguez-Frias, María Dolores Macià, Ana Escarda, Juan Ignacio Esteban, Josep Quer

Open access · goldAbstract readCase Reports
In one paragraph

Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Georg von MassowLiver Unit, Liver Diseases - Viral Hepatitis, Vall d'Hebron Institut of Research (VHIR) - Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain.
Damir Garcia-CehicLiver Unit, Liver Diseases - Viral Hepatitis, Vall d'Hebron Institut of Research (VHIR) - Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain.
Josep GregoriLiver Unit, Liver Diseases - Viral Hepatitis, Vall d'Hebron Institut of Research (VHIR) - Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain.
Francisco Rodriguez-FriasCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
María Dolores MaciàUnidad de Microbiología Molecular, Servicio de Microbiología, Instituto de Investigación Sanitaria de les Illes Balears (IdISBa), Hospital Universitario Son Espases, Mallorca, Spain.
Ana EscardaDigestive Department, Hospital Universitario Son Espases, Mallorca, Spain.
Juan Ignacio EstebanLiver Unit, Liver Diseases - Viral Hepatitis, Vall d'Hebron Institut of Research (VHIR) - Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain.
Josep QuerLiver Unit, Liver Diseases - Viral Hepatitis, Vall d'Hebron Institut of Research (VHIR) - Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain.
Instituto de Salud Carlos III · ESUniversitat Autònoma de Barcelona · ESHealth Research Institute of the Balearic Islands · ESHospital Universitario Son Espases · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.

Indexed as

direct-acting antiviralsgenotype 1HCVsubtype

Identifiers

PMID31118701
PMCPMC6499441
OpenAlexW2940908103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.